Navigation Links
Human albumin from tobacco plants

Human serum albumin (HSA) is the intravenous protein most commonly used in the world for therapeutic ends. It is employed to stabilise blood volume and to avoid risk of a heart attack, its administration in operating theatres being almost a daily occurrence. It is used for haemorrhages, burns, surgical operations or when the patient shows symptoms of malnutrition or dehydration, chronic infections and renal or liver illnesses. The annual consumption in Spain is about 10 tons but, at a worldwide level, the demand exceeds 500 tons.

Agricultural engineer, Alicia Fernández San Millán, has developed a novel technique in Spain - plastidial transformation, in order to produce, in a recombinant form, human albumin from tobacco plants. According to her PhD thesis, plastidial transformation is an economically viable alternative, as it enables increasing the levels of HSA by between 10 and a 100 times, compared to levels obtained by nuclear transformation.

The title of the PhD is: "Production of human serum albumin in tobacco plants by means of plastidial transformation". It should be added that this novel technique, fruit of Ms Fernández San Millán's PhD, has been patented at a world level and there is already a company interested in marketing it.

An efficacious and cheap alternative

Commercial albumin is currently extracted from blood, but the lack of sufficient reserves to cover all worldwide needs has instigated researchers to look for new formulae to multiply this protein. One of the methods most used has been the obtention of HSA from yeasts and mammal cells. However, their high market-place costs have meant that these methods are not competitive. While the price at the pharmacy of albumin produced using plasma is 4 euros per gram, that obtained from yeasts or mammal cells costs between 300 and 4,000 euros per gram. Another option worked on over recent years has been the production of albumin from vegetables, always using nuclear tr ansformation.

The novelty in this research arises from the method of obtention of the HSA. The plastidial system enables the extraction of great quantities of albumin. With nuclear transformation, the maximum level obtained is 0.5% of the total soluble protein of the plant, while application of the plastidial system multiplies this percentage by fourteen (to 7%), reaching an average of 0.9 milligrams of HSA per gram of fresh leaf weight.

The key is the place where the gene in question is deposited. With the nuclear transformation method, it integrates into the DNA of the cell nucleus of the leaf and, thus, can only manage a small number of copies of the gene. With the plastidial system, on the other hand, the gene is introduced into the chloroplast, where photosynthesis takes place and where the genomes can multiply up to 10,000 times.

A property highly valued by the experts has to be added to these positive results: the production of albumin from plants using this technique does not involve the escape of genes through pollen transmission given that, with most crops under cultivation, the genome of the plastids is inherited maternally.

More biomass in tobacco plants

The tobacco plant is very easy to handle genetically and also it is great generator of biomass. The authoress of the thesis says that up to 100 tons of biomass per hectare can be obtained in optimum growth conditions. "Given that the protein is produced in the chloroplasts, the more the leaf biomass we have, the more albumin we can get".

To date all the trials undertaken with tobacco plants have been with laboratory varieties. The aim is to do tests with commercial varieties. Laboratory plants are very small and, as a result, the quantity of albumin extracted is not sufficient. However, the commercial varieties of tobacco are some 30 times more productive in terms of biomass.

Despite the advantages demonstrated by the experts, there is st ill a long way to go. Involving, as it does, a protein that is intravenously injected into patients, it has to be thoroughly purified to eliminate any kind of contaminant. Moreover, it is necessary to assure that the protein obtained has an identical structure to the human one to guarantee that its functioning will be 100%.


'"/>

Source:Elhuyar Fundazioa


Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. New Clues Add 40,000 Years to Age of Human Species
3. Human Cells Filmed Instantly Messaging for First Time
4. Govt Creates Gene Database of Normal Human Tissues
5. Analysis Of Human Genome To Predict The Development Of Illnesses
6. Human Eggs Can Develop From Ovarian Surface Cells In Vitro
7. Determining The Fate Of Cells In The Human Body
8. Whole genome promoter mapping - Human Genome Project v2.0?
9. Human embryonic stem cells have the potential to develop into eggs and sperm in the laboratory
10. Going To Extremes To Improve Human Health
11. Human brain is still evolving
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, 2017 /PRNewswire/ ... 23andMe , the leading personal genetics company, are ... can now provide customers with personalized nutrition plans that ... biometrics, but also genetic markers impacting how their body ... personalized food decision support platform uses biometrics such as ...
(Date:3/2/2017)... 2, 2017 Summary This report ... Merck KGaA and its partnering interests and activities since ... Description The Partnering Deals and Alliance since 2010 ... of one of the world,s leading life sciences companies. ... purchase to ensure inclusion of the most up to ...
(Date:2/28/2017)... 28, 2017 News solutions for biometrics, bag ... ... from 14 to 16 March, Materna will present its complete ... seamless travel is a real benefit for passengers. To accelerate ... their passenger touch point solutions to take passengers through the complete ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... , March 23, 2017 In ... four equities in the Biotech industry: Sangamo Therapeutics Inc. ... Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from ... their free report at: ...
(Date:3/22/2017)... , ... March 22, 2017 , ... ... human tissue regeneration from small lab samples to full-size tissues, bones, even whole ... establish a vascular system that delivers blood deep into the developing tissue. ...
(Date:3/22/2017)... 2017 Good Start Genetics, a leading family ... 130 million covered lives mark through its most recent ... Texas . With newly signed contracts nationally and ... strong payor acceptance based on the quality of its ... counseling, its industry-leading customer care and support and its ...
(Date:3/22/2017)... , March 22, 2017 ... fragmented, states a research report by Transparency Market Research ... Inc., Amgen Inc., and AbbVie Inc., accounted for a ... The prominent players in this market are focusing aggressively ... product portfolio, which is likely to lead to market ...
Breaking Biology Technology: